Press release

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

20210114 Transgene - Appointment Gaelle Stadtler_EN

By nh|2021-01-15T12:11:04+01:00January 14th, 2021|Press release|Comments Off

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 - CTA Approval BT-001 - EN

By nh|2020-12-18T15:09:42+01:00December 21st, 2020|BT-001, BT-001, Press release|Comments Off

Transgene Announces Investor Meetings for January 2021

20201216 PR Investors Meeting agenda Jan 2021

By nh|2020-12-16T16:49:10+01:00December 16th, 2020|Press release|Comments Off

Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

20201203 - TG4001 mini oral prez ESMO IO EN

By nh|2020-12-03T18:24:25+01:00December 3rd, 2020|Press release, TG4001, TG4001|Comments Off

Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer

20201203 - Nomination Transgene - EN

By nh|2020-12-03T17:32:38+01:00December 3rd, 2020|Press release|Comments Off

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201109 Transgene BioInvent_SITC BT001_EN

By nh|2020-12-09T17:51:03+01:00November 9th, 2020|BT-001, BT-001, Invir.IO, Press release|Comments Off

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

20201109 - TG4001+avelumab presentation poster SITC - EN

By nh|2020-11-09T16:44:54+01:00November 9th, 2020|Press release, TG4001, TG4001|Comments Off

Transgene reports business update and end Q3 2020 financial position

20201105 Transgene Q3 business upradta EN

By nh|2020-11-05T16:56:31+01:00November 5th, 2020|Press release|Comments Off

Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit

20201105 TG - Neoantigen summit presentation

By nh|2020-11-04T16:18:15+01:00November 5th, 2020|Press release, TG4050|Comments Off

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 - TG4001+avelumab abstract data SITC - EN

By @CcR34Tg|2020-10-26T18:53:22+01:00October 27th, 2020|Press release, TG4001, TG4001|Comments Off